Last update at 2025-01-22T19:04:00Z
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | -33.01700M | -24.77400M | -22.21500M | -21.89905M | -23.65396M |
Minority interest | - | - | - | - | - |
Net income | -31.93000M | -24.58400M | -22.03700M | -21.72666M | -23.65396M |
Selling general administrative | 12.00M | 8.08M | 6.31M | 5.52M | 6.73M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 1.03M | 1.14M | - | - | 0.00000M |
Reconciled depreciation | 0.70M | 0.52M | 0.45M | 0.42M | 0.05M |
Ebit | -34.10400M | -24.96400M | -22.39300M | -22.07145M | -23.82732M |
Ebitda | -33.40500M | -24.44000M | -21.94600M | -21.65136M | -23.77660M |
Depreciation and amortization | 0.70M | 0.52M | 0.45M | 0.42M | 0.05M |
Non operating income net other | - | - | - | - | - |
Operating income | -34.10400M | -24.96400M | -22.39300M | -22.07145M | -23.82732M |
Other operating expenses | 35.13M | 26.11M | 22.39M | 22.07M | 23.83M |
Interest expense | -1.08700M | 0.19M | 0.00000M | 0.00000M | 0.17M |
Tax provision | - | - | - | - | - |
Interest income | 1.09M | 0.19M | 0.18M | 0.17M | 0.17M |
Net interest income | 1.09M | 0.19M | 0.18M | 0.17M | 0.17M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | -1.08700M | -0.19000M | -0.17800M | -0.17239M | 0.17M |
Total revenue | 1.03M | 1.14M | 0.00000M | 0.00000M | 0.00000M |
Total operating expenses | 35.13M | 26.11M | 22.39M | 22.07M | 23.83M |
Cost of revenue | - | - | - | - | 0.00000M |
Total other income expense net | 1.09M | 0.19M | 0.18M | 0.17M | 0.17M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | -33.01700M | -24.77400M | -22.21500M | -21.89905M | -23.65396M |
Net income applicable to common shares | -33.01700M | -24.77400M | -22.21600M | -21.90032M | -23.65396M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Total assets | 81.44M | 114.19M | 80.39M | 66.40M | 11.67M |
Intangible assets | - | - | - | - | - |
Earning assets | - | - | - | - | - |
Other current assets | 1.59M | 2.03M | 1.92M | 1.36M | 0.83M |
Total liab | 45.07M | 47.71M | 6.84M | 5.08M | 6.03M |
Total stockholder equity | 36.38M | 66.48M | 73.55M | 61.32M | 5.64M |
Deferred long term liab | - | - | - | - | - |
Other current liab | -0.54100M | -24.87000M | 6.53M | 4.34M | 4.60M |
Common stock | 0.03M | 0.03M | 0.02M | 0.02M | 0.16M |
Capital stock | 0.03M | 0.03M | 0.02M | 0.02M | 0.16M |
Retained earnings | -337.58300M | -288.76500M | -255.74800M | -230.97400M | -208.75756M |
Other liab | - | 35.00M | - | - | - |
Good will | - | - | - | - | - |
Other assets | 0.00000M | 0.30M | - | 1.16M | 0.44M |
Cash | 76.68M | 108.91M | 77.83M | 63.56M | 9.25M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 8.49M | 10.63M | 6.84M | 4.77M | 5.34M |
Current deferred revenue | 35.00M | 35.00M | - | -4.34000M | - |
Net debt | -74.56400M | -106.32900M | -77.51900M | -62.82200M | -7.82571M |
Short term debt | 1.08M | 0.50M | 0.31M | 0.43M | 0.75M |
Short long term debt | - | - | - | - | 0.38M |
Short long term debt total | 2.11M | 2.58M | 0.31M | 0.74M | 1.43M |
Other stockholder equity | 373.93M | 355.22M | 329.27M | 292.27M | 214.24M |
Property plant equipment | - | 2.95M | 0.64M | 1.03M | 1.14M |
Total current assets | 78.26M | 110.94M | 79.75M | 64.92M | 10.09M |
Long term investments | - | - | - | - | - |
Net tangible assets | - | 66.48M | 73.55M | 61.32M | 5.64M |
Short term investments | - | - | - | - | - |
Net receivables | - | - | - | - | - |
Long term debt | - | - | - | - | - |
Inventory | - | - | - | - | - |
Accounts payable | 7.95M | 10.13M | 5.54M | 4.34M | 4.60M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | - | - | - | - | -0.23742M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | 0.02M | 0.02M | 0.16M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | -255.74800M | -230.97400M | -208.75756M |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 0.31M | 0.30M | 0.06M | 0.44M | 0.44M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 3.18M | 3.25M | 0.64M | 1.47M | 1.58M |
Capital lease obligations | 2.11M | 2.58M | 0.31M | 0.74M | 1.05M |
Long term debt total | - | - | - | - | 0.15M |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | -0.36600M | -0.13300M | -0.25300M | -0.06389M | -0.09609M |
Change to liabilities | 38.60M | 1.20M | -0.25700M | -1.25574M | 1.13M |
Total cashflows from investing activities | -0.36600M | -0.13300M | -0.25300M | -0.06389M | -0.09609M |
Net borrowings | -0.04900M | -0.08500M | -0.46000M | -0.24924M | 0.02M |
Total cash from financing activities | 23.11M | 35.22M | 76.18M | 17.11M | 16.98M |
Change to operating activities | -0.43000M | 0.49M | -0.84600M | -0.02145M | 0.10M |
Net income | -33.01700M | -24.77400M | -22.21500M | -21.89905M | -23.65396M |
Change in cash | 31.39M | 14.22M | 54.31M | -4.41126M | -3.68606M |
Begin period cash flow | 78.22M | 64.00M | 9.69M | 14.10M | 17.79M |
End period cash flow | 109.61M | 78.22M | 64.00M | 9.69M | 14.10M |
Total cash from operating activities | 8.64M | -20.86600M | -21.61700M | -21.46145M | -20.57106M |
Issuance of capital stock | 23.16M | 35.30M | 76.59M | 15.93M | 16.98M |
Depreciation | 0.70M | 0.52M | 0.45M | 0.42M | 0.05M |
Other cashflows from investing activities | - | - | - | - | - |
Dividends paid | - | - | -0.00100M | -0.00127M | - |
Change to inventory | - | - | - | - | - |
Change to account receivables | - | - | - | - | - |
Sale purchase of stock | - | 35.31M | 0.00100M | 0.00127M | 16.98M |
Other cashflows from financing activities | -0.36600M | 0.00600M | 0.05M | 1.50M | 0.00485M |
Change to netincome | 2.79M | 1.69M | 1.25M | 1.29M | 1.80M |
Capital expenditures | 0.37M | 0.13M | 0.25M | 0.06M | 0.10M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | -0.50300M | -0.84600M | -0.02145M | 0.10M |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | 14.22M | 54.31M | -4.41126M | -3.68606M |
Change in working capital | 38.17M | 1.69M | -1.10300M | -1.27719M | 1.23M |
Stock based compensation | 2.79M | 1.69M | 1.25M | 1.29M | 1.80M |
Other non cash items | - | -11.06100M | -56.51700M | 2.25M | 6.14M |
Free cash flow | 8.28M | -20.99900M | -21.87000M | -21.52534M | -20.66715M |
Sector: Healthcare Industry: Biotechnology
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
ATNM Actinium Pharmaceuticals Inc |
0.02 1.54% | 1.32 | - | 6.84 | 508.38 | 1.08 | 1726.07 | -3.6241 |
NVO Novo Nordisk A/S |
-0.4 0.49% | 80.63 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
NONOF Novo Nordisk A/S |
0.78 0.97% | 81.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
VRTX Vertex Pharmaceuticals Inc |
1.96 0.46% | 429.85 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
REGN Regeneron Pharmaceuticals Inc |
-3.1 0.45% | 684.70 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
100 Park Avenue, New York, NY, United States, 10017
Name | Title | Year Born |
---|---|---|
Mr. Sandesh C. Seth M.B.A., M.S., MBA | Chairman & CEO | 1964 |
Mr. Steven O'Loughlin BS | CFO & Corp. Sec. | 1986 |
Dr. Paul Diamond Esq., Ph.D. | VP of Patent & Legal Counsel | NA |
Dr. David Gould | Sr. VP of Corp. Devel. & Corp. Affairs | NA |
Dr. Bernie Cunningham P.M.P., Ph.D. | Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management | NA |
Dr. Qing Liang | VP & Head of Radiation Sciences | NA |
Dr. Robert N. Daly M.S., Ph.D. | VP & Head of Clinical Operations | NA |
Dr. Mamata Gokhale | VP & Global Head of Regulatory Affairs | NA |
Dr. Avinash Desai M.D. | Chief Medical Officer | NA |
Dr. Arun Swaminathan Ph.D. | Chief Bus. Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.